So proud of ⁦MGH Thoracic Oncology⁩ colleague ⁦JessicaJLinMD⁩ for her nuanced, eloquent and inspiring discussion at #ASCO24 lung oral session, reviewing data from ⁦Ben Solomon⁩ Natasha Leighl and Enriqueta Felipe. Great job Jess!

Congratulations to our @penncancer stars who will no doubt change the world and help so many patients. We are so proud and thrilled for you! @pennmedicine #ASCO24 Conquer Cancer, the ASCO Foundation

The best part of ASCO #ASCO24 is hanging with my Penn Medicine - Abramson Cancer Center Penn Medicine Penn Medicine MD team Lova Sun Melina Marmarelis Angie DeMichele, MD, MSCE, FASCO Robin Zon, MD, FACP, FASCO Ravi B. Parikh Steven Brem Penn Cancer Innovation #PennPeeps

Very impressive work by Helena- especially as an IIT study- great effort in a key but poorly studied subset My #lcsm friends- Yu all should check this out!

The new standard of care is consolidation immunotherapy for limited stage small cell lung cancer & the first systemic therapy advance for limited small cell in ~50yrs. Allied to Laura we had fun on the ASCO non-metastatic NSCLC/SCLC/meso track committee this year! #lcsm #ASCO24

ADRIATIC. A brilliant presentation by David R. Spigel, MD, FASCO and discussion by Lauren Averett Byers, MD. I really reflected on the comment about despite similar HR’s, the absolute extensions are massive in LSvES. BTOG #ASCO24

Exciting times ahead for #sclc ! But today is a pretty good start #adriatic #ASCO24 Lauren Averett Byers, MD #lcsm

We are so proud to be part of “House of Lynn” Robin Zon, MD, FACP, FASCO ASCO #ASCO24 Grateful to have fantastic leadership in the house Angie DeMichele, MD, MSCE, FASCO Penn Medicine - Abramson Cancer Center Penn Medicine Penn Medicine MD OncoAlert Penn Cancer Innovation

Wonderful presentation by Michael Offin from MSK Department of Medicine Memorial Sloan Kettering Cancer Center showing day from investigator initiated trial of chemo+nivo in mesothelioma, demonstrating feasibility.

#ASCO24 Dr. Melina Marmarelis asks: are we on BEAT? Are there additive effects of immunotherapy and VEGF inhibition? The discordance between PFS and OS is not new: consider toxicity, crossover, unique mechanisms. Overall, no clear role demonstrated (yet) in unselected population.

Janus kinase (JAK) inhibitors improve antitumor responses Science Magazine Melina Marmarelis Andy Minn E. John Wherry Veronika Bachanova MD Teijaro Lab science.org/doi/10.1126/sc… science.org/doi/10.1126/sc… science.org/doi/10.1126/sc…

Lucky to work with this amazing team. This was team science at its best! 🤩✨Can’t wait to continue building on this work. Penn Medicine - Abramson Cancer Center Joshua Bauml, MD Charu Aggarwal, MD, MPH, FASCO Corey Langer

JAK of all trades? Interesting papers on JAK inhibition augmenting IO response in NHL and NSCLC as well

Summary of our paper scim.ag/7p1 on combining JAK inhibitors with anti-PD1 for lung cancer (NSCLC). Part of a bench-to-bedside journey to understand opposing roles of IFN in IO. Wonderful team w E. John Wherry Divij Caitlin Foley Melina Marmarelis Joshua Bauml, MD et al! 1/13

Our own Dr. Melina Elpi Marmarelis (Melina Marmarelis) commented on the results of a study presented at #ASCO24 that showed progress in treating resectable diffuse pleural #mesothelioma. VJ Oncology spr.ly/6014g51bp

When you are lucky to have colleagues who become your BFFs 😇 Melina Marmarelis Lova Sun Aditi Singh Penn Medicine - Abramson Cancer Center Penn Cancer Innovation Penn Medicine News

🔥#WCLC24 abstracts titles 💉Novel Immunotherapy Strategies and Combinations ✅Chairs: Cheryl Ho Anil Tibdewal 🎙️Melina Marmarelis 🎯Phase II Study of Pembrolizumab and Itacitinib for Patients with Metastatic NSCLC Expressing PD-L1 #LCSM IASLC OncoAlert cattendee.abstractsonline.com/meeting/20598

Our #METworking paper in collaboration with Caris Life Sciences now in Lung Cancer Journal #lcsm METCrusaders - METex14+ nSq have improved OS vs Sq - METex14 + receiving IO have improved OS compared to those who did not receive IO - POT1 enriched independent of histology -⬇️ prevalence

Melina Marmarelis presenting combination Pembro + JAKi. Interesting data in treatment naive patients shown in slide with 4 responses. Those that respond to Pembro alone vs PR after adding JAKi. ORR 66% mOS 53.4months #WCLC24

📣 And that is a wrap for #WCLC24 Learned so much from my amazing colleagues Prof Yi-Long Wu Henning Willers, MD Melina Marmarelis in this educational session “Intensifying Suboptimal Response to Targeted Therapy Session Type” chaired by Susan Combs Scott, MD See you all in Barcelona next year!